VRDN SCHEDULE 13G/A: SEC filing
T. Rowe Price Associates
Filed with the SEC on · accession 0000080255-26-000699
VRDN filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. T. Rowe Price Associates filed an amended Schedule 13G reporting beneficial ownership of 5,123,592 shares, or 4.5%, of Viridian Therapeutics common stock as of September 30, 2026. The stock moved -3.5% by the first close after the filing.
Summary of the filing
T. Rowe Price Associates filed an amended Schedule 13G reporting beneficial ownership of 5,123,592 shares, or 4.5%, of Viridian Therapeutics common stock as of September 30, 2026. The filing is a passive investment disclosure with no intent to influence control of the company.
Key details
How VRDN stock reacted
Close before
$30.87
Nov 13, 2026
First close after
-3.47%
$29.80
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for VRDN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for VRDN?
Click hereFrequently asked questions
What did VRDN file with the SEC on Nov 16, 2026?
VRDN filed a SCHEDULE 13G/A (SEC filing). T. Rowe Price Associates filed an amended Schedule 13G reporting beneficial ownership of 5,123,592 shares, or 4.5%, of Viridian Therapeutics common stock as of September 30, 2026. The filing is a passive investment disclosure with no intent to influence control of the company.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
How did VRDN stock react to this filing?
VRDN closed at $30.87 before the filing and $29.80 on Nov 16, 2026 (-3.47%).
Other VRDN SEC filings
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- SCHEDULE 13G · SEC filingNov 10, 2026
- 8-K · Fda approvalNov 9, 2026
- 8-K · SEC filingNov 4, 2026
- 10-Q · SEC filingNov 4, 2026
- SCHEDULE 13G · SEC filingAug 20, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G · SEC filingAug 14, 2026
Get alerts when VRDN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days